Radiopharm Theranostics Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported net loss was AUD 30.34 million. Basic loss per share from continuing operations was AUD 0.1674.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.036 AUD | -8.86% | -10.00% | -51.35% |
08/05 | Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities | MT |
29/02 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.35% | 10.87M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- RAD Stock
- News Radiopharm Theranostics Limited
- Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2022